Autologous exosomes in skin regeneration

AUTHOR:

Dr. Jacek Nowak, PhD

dentist and aesthetic medicine doctor

Aesthetic medicine is increasingly shifting toward biological therapies that not only improve the appearance of the skin but also actively stimulate its natural repair mechanisms. One of the most promising directions is the use of autologous exosomes, now considered among the most powerful biological carriers of regeneration.

Dr. Jacek Nowak, PhD, dentist and aesthetic medicine physician, a specialist in PRP and PRF-based treatments, discusses the AutologIX procedure, which utilizes a concentrate of exosomes derived from platelet-rich plasma.

What are exosomes?

Exosomes are microscopic, membrane-bound extracellular nanovesicles (EVs) with a diameter of just 30–150 nm. They are formed inside cells through endocytic processes and are secreted by nearly all cell types. They originate via the endosomal pathway and are released through the fusion of multivesicular endosomes (MVEs) with the cell membrane.

Exosomes have been identified in numerous body fluids, including blood, urine, saliva, synovial fluid, amniotic fluid, breast milk, and cerebrospinal fluid.

Their uniqueness lies in their biological function: exosomes are natural carriers of intercellular communication. They transport proteins, lipids, and genetic material (mRNA, microRNA), which can precisely modulate the activity of target cells. Both paracrine and autocrine signaling largely occur through these vesicles.

In 2013, the Nobel Prize in Physiology or Medicine was awarded to Randy Schekman, James Rothman, and Thomas Südhof for discoveries of the mechanisms regulating vesicular transport and communication within cells. Schekman identified genes essential for vesicle transport, Rothman described the protein machinery enabling vesicle fusion with target cells, and Südhof explained how signals regulate the precise release of vesicular cargo.

Due to their characteristic protein markers and uniform structure, exosomes are considered the most functionally advanced fraction of extracellular vesicles.

Plasma-derived exosomes

Exosomes present in plasma form a heterogeneous population originating from various cell types, including leukocytes, erythrocytes, and endothelial cells. However, it is estimated that over 25% of circulating extracellular vesicles in plasma are derived from platelets (PL-EXOs).

Exosomes are currently regarded as one of the key factors in stem cell secretions, underlying their regenerative and immunomodulatory capabilities in tissue repair. Once internalized by stem cells, exosomal content (including peptides, transcription factors, miRNA, long RNA chains, and DNA quadruplexes) is released into the cell. This process induces forward signaling, long-term potentiation, and intracellular memory formation, significantly influencing stem cell metabolism and regenerative potential.

Various methods are used to isolate and concentrate platelet-derived exosomes. AutologIX is based on a two-phase protocol:

• a centrifugation phase that initiates platelet activation and partial exosome release,
• followed by a filtration phase that mechanically stimulates platelets, increasing exosome release by an additional 30–40%.

As a result, filtration significantly increases PL-Exo concentration. The exosome concentrate is also rich in growth factors such as PDGF, TGF-β, VEGF, bFGF, EGF, IGF-1, and IGF-2.

Thanks to their high biocompatibility and low cytotoxicity, tumorigenicity, and immunogenicity, platelet-derived exosomes demonstrate strong therapeutic potential and remain a major focus in regenerative medicine.

What does the AutologIX procedure look like?

This method utilizes advanced ultrafiltration technology (molecular filtration at 15 kDa, pore size <5 nm). In the AutologIX protocol, exosomes are released from platelets during PRP centrifugation and remain suspended in plasma. The process can be performed using standard PRP tubes with a separation gel.

The plasma is then filtered using the ProtSmart 6 device—a medical-grade capillary filter with pore size <5 nm and a filtration cutoff of approximately 15,000 kDa. During this process, water and salt ions are removed into a filtration bag, while exosomes, plasma proteins, and cellular components are retained in the syringe and can be administered via mesotherapy.

The system allows processing of 20–30 ml of plasma to obtain 5–7 ml of a highly concentrated final product with significantly increased exosome content.

AutologIX achieves a fivefold concentration of all biological regenerative components, including exosomes, growth factors (PDGF, TGF-β, VEGF, FGF), cytokines, plasma proteins, platelets, and fibrin. Studies confirm extremely high concentrations—up to 26.4 trillion particles/ml—significantly exceeding those of competing methods.

As a result, treatments are highly effective, with clinical outcomes often visible after a single session.

The effects are long-lasting due to the sustained impact of PL-Exo on cellular metabolism within the treated area (including MSCs and ASCs). Treatments typically need to be repeated only after 9–16 months, depending on patient age and skin condition.

In hair loss therapy, two sessions spaced 2–3 months apart are recommended. Treatment plans should always be individualized.

Advantages of AutologIX

• Extremely high particle concentration—up to 26.4 trillion particles/ml
• No biological loss—conversion of 20–30 ml plasma into 5–7 ml concentrate
• Multidirectional regeneration—47% higher PDGF-bb and 50% more total plasma proteins compared to diluted plasma therapies
• Result: fivefold concentrated plasma with activated platelets and exosomes
• Scientific validation and standards—compliant with MISEV2023 guidelines and certified as a Class IIa medical device

How do exosomes work in the skin?

Exosomes exert multidirectional regenerative and rejuvenating effects:

• stimulate fibroblasts and keratinocytes, enhancing proliferation and migration
• increase collagen and elastin synthesis, improving density, firmness, and elasticity while reducing fine lines
• accelerate wound healing and re-epithelialization
• support angiogenesis and microcirculation, improving tissue oxygenation and nutrition; they may also reduce persistent erythema
• exhibit anti-inflammatory properties, supporting treatment of acne, psoriasis, and eczema

Clinical outcomes include:

• skin revitalization and regeneration with improved tone, texture, and uniformity
• reduction of wrinkles and fine lines
• improved skin firmness and density
• faster healing after invasive procedures
• treatment of hair loss (alopecia areata and androgenetic alopecia) and support for hair transplantation
• reduction of inflammation and redness
• improvement of acne scars

Summary

Autologous exosomes represent one of the most advanced and promising directions in regenerative therapies. In practice, they are currently the only exosome-based product suitable for injection. Other exosome-containing products available on the market are plant-derived and can only be used topically.

In my clinical practice, I perform numerous PRP and fibrin treatments, and the ability to obtain autologous exosome concentrates significantly expands the range of effective biological procedures.

With a simple protocol, it is possible to isolate highly pure, therapeutically relevant exosomes with enhanced efficiency through mechanical activation. This makes AutologIX particularly valuable for patients with severely damaged or photoaged skin, acne scars, and as part of anti-aging prevention—regardless of age.

Similarly to PRP, and potentially even more effectively, platelet-derived exosomes show promise in wound healing and dentistry. In practice, a single AutologIX treatment may match the efficacy of several standard PRP or PRF procedures, with fewer sessions and faster visible results. Importantly, the effects are longer-lasting due to the mechanism of action of exosomes and their influence on target cells.

It is also worth noting that as of this year, a horizontal centrifuge is no longer required to prepare exosome concentrates from PRP. Standard PRP centrifuges and gel tubes can now be used, making this highly effective and easy-to-prepare regenerative procedure more accessible to clinics.

Data sources (AutologIX):

• Autologix Scientific Validation Framework: MISEV2023 Compliant. Characterization Protocol. MEDICA S.p.A., 2024
• Autologix Clinical Validation Study. Alessandria Transfusion Center, Italy. Lead Investigator: Dr. Laura Mazzucco, 2024
• Phase I Clinical Safety Study Results, Autologix Clinical Documentation (n=30 patients), 2024